



Published in final edited form as:

Clin Infect Dis. 2013 September ; 57(5): 639–647. doi:10.1093/cid/cit357.

Investigation of a *Chlamydia pneumoniae* Outbreak in a Federal Correctional Facility in Texas

Laura Conklin^{1,a}, Jennifer Adjemian^{2,a}, Jennifer Loo¹, Sema Mandal^{1,4}, Carol Davis³, Sharyn Parks^{3,4}, Tina Parsons², Brian McDonough², Jorge Partida², Kathleen Thurman¹, Maureen H. Diaz¹, Alvaro Benitez¹, Tracy Pondo¹, Cynthia G. Whitney¹, Jonas M. Winchell¹, Newton Kendig², and Chris Van Beneden¹

¹Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

²United States Federal Bureau of Prisons, Washington, District of Columbia

³Emerging and Acute Infectious Diseases Branch, Texas Department of State Health Services, Austin

⁴Epidemic Intelligence Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, Georgia

Abstract

Background—*Chlamydia pneumoniae* illness is poorly characterized, particularly as a sole causative pathogen. We investigated a *C. pneumoniae* outbreak at a federal correctional facility.

Methods—We identified inmates with acute respiratory illness (ARI) from 1 November 2009 to 24 February 2010 through clinic self-referral and active case finding. We tested oropharyngeal and/or nasopharyngeal swabs for *C. pneumoniae* by real-time polymerase chain reaction (qPCR) and serum samples by microimmunofluorescence. Cases were inmates with ARI and radiologically confirmed pneumonia, positive qPCR, or serological evidence of recent infection. Swabs from 7 acutely ill inmates were tested for 18 respiratory pathogens using qPCR TaqMan Array Cards (TACs). Follow-up swabs from case patients were collected for up to 8 weeks.

Results—Among 33 self-referred and 226 randomly selected inmates, 52 (20.1%) met the case definition; pneumonia was confirmed in 4 by radiology only, in 9 by qPCR only, in 17 by serology only, and in 22 by both qPCR and serology. The prison attack rate was 10.4% (95% confidence interval, 7.0%–13.8%). White inmates and residents of housing unit Y were at highest risk. TAC testing detected *C. pneumoniae* in 4 (57%) inmates; no other causative pathogens were identified. Among 40 inmates followed prospectively, *C. pneumoniae* was detected for up to 8 weeks. Thirteen (52%) of 25 inmates treated with azithromycin continued to be qPCR positive >2 weeks after treatment.

Correspondence: Laura Conklin, MD, Division of Bacterial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS C-25, Atlanta, GA 30333 (lconklin@cdc.gov).

^aL. C. and J. A. contributed equally to this work.

Disclaimer. Opinions expressed in this article are those of the authors and do not necessarily represent the opinions of the Federal Bureau of Prisons, the Department of Justice, or the Centers for Disease Control and Prevention.

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Conclusions—*Chlamydia pneumoniae* was the causative pathogen of this outbreak. Higher risk among certain groups suggests that social interaction contributed to transmission. Persistence of *C. pneumoniae* in the oropharynx creates challenges for outbreak control measures.

Keywords

Chlamydia pneumoniae; *Chlamydophila*; atypical pneumonia; community-acquired pneumonia; prison

Chlamydia (Chlamydophila) pneumoniae is an obligate intracellular bacterium commonly associated with both upper and lower respiratory tract infections including pharyngitis, bronchitis, and pneumonia. First described in 1986, *C. pneumoniae* infections generally consist of low-grade fever, prolonged cough, coryza, headache, myalgias, and laryngitis [1, 2]. Macrolides are a common first-line treatment; however, tetracyclines and fluoroquinolones are also effective. Symptoms may resolve without antibiotics and asymptomatic infection can occur [3–5].

Chlamydia pneumoniae is endemic world-wide. Outbreaks occur periodically and without a clear seasonal pattern, primarily in close-contact settings among high-risk populations such as in long-term care facilities [6–8]. *Chlamydia pneumoniae* is frequently detected alongside other respiratory pathogens, making its role as a primary disease-causing pathogen unclear [9–11]. The diagnosis of *C. pneumoniae* infection is commonly made through commercially available serological assays, despite poor sensitivity and specificity due to high background seroprevalence and potential cross-reaction with other *Chlamydia* species [12]. More recently, real-time polymerase chain reaction (qPCR) assays are being used to identify *C. pneumoniae* from respiratory specimens that are highly sensitive and specific for acute *C. pneumoniae* infection but are unable to provide a retrospective diagnosis [13–15].

During November 2009–February 2010, an outbreak of pneumonia was identified in a male federal correctional institution in Texas. Symptoms included low-grade fever, dry cough, and body aches, and illness appeared to occur in previously healthy inmates. Four inmates were hospitalized. Sputum and blood cultures, sputum testing for acid-fast bacilli, and urine testing for *Legionella* and *Histoplasma* were negative. This report describes the outbreak's laboratory and epidemiological investigation, and illustrates the challenges of implementing outbreak control interventions in this setting.

METHODS

Outbreak Setting and Pathogen Identification

The facility's 1574 inmates resided in 2 housing units, each with 3 floors. Although housing units were racially mixed, inmates comingled along ethnic (or gang) lines in common areas. Healthcare services were available for a nominal fee and smoking was not permitted on the premises. Upon suspicion of the outbreak, ill inmates were placed in single-celled housing units until their symptoms improved. Nasopharyngeal (NP) and oropharyngeal (OP) specimens available from 7 acutely ill inmates were sent to the Centers for Disease Control and Prevention (CDC) for multiple respiratory pathogen testing to rapidly identify the etiology.

Case Finding and Estimation of Attack Rate

We reviewed available prison medical records on 33 of 36 inmates who had self-referred to the facility's infirmary during the outbreak period (1 November 2009–24 February 2010) and had been diagnosed with suspected or confirmed pneumonia. To establish a facility-wide attack rate and identify *C. pneumoniae* infection among inmates who did not seek medical care, we conducted active case finding among a systematic random sample of inmates. The sample size was calculated based on an expected maximum attack rate of 20% and 10% refusal rate; 270 beds were selected (17.5% of the inmate population). Beds were selected from a list of all bed numbers at the facility (minus known pneumonia cases) sorted by building, floor, and bunk (upper or lower).

Consenting inmates, both randomly selected and self-referred, were interviewed using a standardized questionnaire to collect demographic and clinical information, details on housing assignments, and general activities within the prison. Race categories were assigned by the Federal Bureau of Prisons (BOP). Information on past medical history was obtained via inmate report, prison records, and BOP's electronic medical records. Inmates provided NP and OP, or combined NP/OP, swabs, except in cases where collection of 1 type of swab (NP or OP) was refused. Acute and convalescent sera for *C. pneumoniae*-specific serologies (immunoglobulins M [IgM] and G [IgG]) were collected from consenting participants who were symptomatic during the interview or who had experienced an acute respiratory infection within the previous month.

Case Definitions

We defined a case of *C. pneumoniae* illness as acute respiratory illness (ARI) in an inmate residing within the facility during the outbreak period supported by either radiological confirmation of pneumonia (noted by 2 independent readers) or laboratory evidence of acute *C. pneumoniae* infection. ARI was defined as myalgias, headache, or sore throat in the presence of cough lasting ≥ 3 days, self-reported fever ≥ 99°F, or self-reported chills. Laboratory evidence of acute infection was defined as *C. pneumoniae* detected by qPCR (from NP, OP, or NP/OP swab), an IgM titer of ≥ 1:10, or a ≥ 4-fold increase in IgG antibody titer between paired sera obtained 3–6 weeks apart. Persons with laboratory evidence of acute *C. pneumoniae* infection without ARI were defined as asymptomatic cases.

Risk Factor Analyses

To identify known risk factors for *C. pneumoniae* infection, we conducted 2 independent analyses using (1) self-referred cases, and (2) randomly selected cases. Persons identified in the systematic random sample who were not identified as cases and had neither an ARI nor laboratory evidence of infection served as controls; persons reporting an ARI without laboratory evidence of infection were excluded from these analyses.

Study of Persistence of *C. pneumoniae* After Infection

We tracked *C. pneumoniae* in the oropharynx after infection by weekly follow-up OP swabs among cases. During each swab collection, inmates reported current symptoms and

antibiotics usage within the preceding 7 days. Participants were followed for up to 8 weeks, until they had 2 consecutive negative samples, or until they declined participation.

Laboratory Analysis

The initial 7 NP/OP swabs from acutely ill inmates were tested using qPCR at the CDC's Respiratory Diseases Branch Laboratory in Atlanta, Georgia, using the TaqMan Array Card (TAC) for influenza (A and B), respiratory syncytial virus, human parainfluenza virus (types 1, 2, and 3), human metapneumovirus, rhinovirus, enterovirus, human parechovirus, adenovirus, *Legionella pneumophila*, *Haemophilus influenzae*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Bordetella pertussis*. Subsequent testing of respiratory and serological specimens was performed at the CDC using methods that have been previously described [15]. In brief, all NP and OP specimens were collected using Dacron swabs and immediately placed in refrigerated universal transport media (Becton Dickinson, Franklin Lakes, New Jersey). Serum samples and swabs were frozen at -20°C within 12 hours and sent to the CDC for analysis. Swabs were tested using a real-time multiplex PCR assay for detection of *C. pneumoniae*, *M. pneumoniae*, *Legionella* species, and a human DNA internal control [16]. Acute and convalescent sera were tested for *C. pneumoniae*-specific IgM and IgG antibodies using commercially available microimmunofluorescence kits (FOCUS Diagnostics, Cypress, California).

Statistical Analysis

Data were analyzed using SAS software, version 9.2 (SAS Institute, Cary, North Carolina). Weighted attack rates were calculated using the proportion of inmates represented by the sample. A suspected pneumonia attack rate was calculated for cases who self-referred for care and was added to the weighted sample attack rate to estimate the facility-wide attack rate. The variance of the estimated facility-wide attack rate included the variance of the weighted sample attack rate and the self-referred cases' attack rate. Odds ratios and 95% confidence intervals comparing self-referred cases to randomly selected controls were calculated from univariate logistic regression models. Relative risks and 95% confidence intervals comparing randomly selected cases to randomly selected controls were calculated from univariate log binomial models.

RESULTS

Descriptive Epidemiology of the Outbreak

Of 36 inmates who self-referred for care during the outbreak, 3 did not meet case criteria. Among the remaining 33, 15 (45.5%) had radiologically confirmed pneumonia and 29 (87.9%) had laboratory confirmation of *C. pneumoniae* infection. Clinical characteristics were incomplete for 6 (Table 1), including 3 who refused to participate in the survey. Among 270 beds randomly selected for active case finding, 254 were occupied at the time of the survey; of these, 223 (87.8%) inmates consented to participate. The random sample identified 19 additional cases, bringing the total number to 52.

Inmates who self-referred for care were older (median age, 42 years) than cases identified by the systematic random sample (median age, 35 years; Table 1). Self-referred cases were also more often white (55.6%) or African American (33.3%), or lived in housing unit Y (69.7%). In contrast, random sample cases were more frequently Hispanic (26.3%) or reported a history of asthma (26.3%). The most common symptoms among cases were cough 3 days (98.0%), runny nose (72.9%), and sore throat (72.9%). The median duration of cough at time of case detection was 21 days (range, 1–64). In general, symptoms were reported more frequently among cases who self-referred compared to those identified through random selection.

Forty-eight cases had laboratory confirmation of *C. pneumoniae* infection; 29 (60.4%) self-referred for care. Among the 15 self-referred cases with radiologically confirmed pneumonia, 9 (60%) tested positive by qPCR for *C. pneumoniae*. Eight (42.1%) cases identified by random selection had a qPCR-positive swab, 14 (87.5%) had elevated IgM, and 1 (25%) of 4 who provided paired sera demonstrated a 4-fold rise in IgG. Eight asymptomatic *C. pneumoniae*-infected inmates were identified during the survey; 1 through a qPCR-positive OP swab and 7 through IgM-positive serologies.

Weighted attack rates for *C. pneumoniae* infection ranged by floor and unit (Table 2), with a facility-wide attack rate of 10.4% (95% confidence interval, 7.0%–13.8%) and the highest attack rate on the second floor of housing unit Y (13.6%). The onset of illness among cases in housing unit Y generally preceded those in housing unit X (Figure 1).

Risk Factor Analysis Findings

A total of 155 inmates from the random sample were without ARI or laboratory evidence of *C. pneumoniae* infection and were identified as controls and independently compared to the 33 self-referred and 19 randomly selected cases. Both self-referred and randomly selected cases were more often of white race compared to Hispanic and reside in housing unit Y, although these findings were statistically significant only for self-referred cases (Table 3). Latino-Hispanic inmates were at lowest risk of infection for self-referred cases. We found no associations with self-reported history of asthma, preincarceration smoking status, educational level, or time spent in any specific areas of the facility.

Laboratory Results

From the 7 NP/OP specimens available for TAC testing, 4 (57.1%) tested positive for *C. pneumoniae* (1 was also positive for *S. pneumoniae*). One each was weakly positive for *S. pneumoniae* and *H. influenzae*, which frequently colonize the upper respiratory tract. Results for all other 15 pathogens were negative. Based on these findings, *C. pneumoniae* was determined to be the sole causative pathogen in the outbreak.

Among 256 randomly sampled and self-referred inmates, we collected combined NP/OP swabs from 66 (25.5%), paired separate NP and OP swabs from 29 (11.2%), only NP from 1 (0.3%), and only OP from 160 (61.8%). Positivity rates were 19.7% among combined NP/OPs, 10% among NPs, and 3.7% among OPs. Among 29 inmates who had NP and OP

swabs collected and tested separately, only 2 had discrepant results; in both cases, OP swabs were positive and NP swabs were negative (data not shown).

Among 122 (47.1%) inmates who submitted single serum samples, 33 (12.7%) submitted paired serum samples 4–6 weeks later. This included 65 inmates who reported an ARI during the outbreak period but who were negative for *C. pneumoniae* infection by qPCR. Of these, 35 (59.3%) had a single IgG titer for *C. pneumoniae* 512 and 17 (28.8%) had a single IgM titer 10 (Table 4). Among 37 inmates with no ARI symptoms and who were negative by qPCR for *C. pneumoniae*, 23 (62.2%) had a single IgG assay and 7 (18.9%) had a single IgM assay showing elevated antibody levels.

Persistence of *C. pneumoniae* After Infection

We collected additional OP swabs on 40 inmates for up to 8 weeks after the initial investigation: 36 individuals met our case definition, 3 described an ARI but did not meet case criteria, and 1 self-referred for care after conclusion of the investigation and tested positive for *C. pneumoniae* by qPCR. For 12 (30.0%) inmates, no *C. pneumoniae* was detected at any visit (Figure 2). Among 28 inmates who tested qPCR positive for *C. pneumoniae* at least once, 6 were positive only on 1 swab; 22 others were positive up to 8 weeks after the outbreak investigation (median, 5 weeks). Sixteen (57.1%) received antibiotic treatment >2 weeks prior to their positive swab (13 with azithromycin; 3 with nonspecified antibiotic). A positive qPCR test was associated with cough in 35 of 69 (50.1%) carriage episodes. Six (30.0%) persons tested positive by qPCR following a single negative swab, and 4 (10.0%) tested positive after 2 consecutive negative swabs. At the time of their last swab, 16 (40%) inmates were both asymptomatic and qPCR-negative.

Public Health Interventions

To stop transmission among inmates, the facility posted educational notices around the prison and encouraged sick inmates to present for care and early initiation of treatment by waiving the usual clinic fee and discontinuing single-cell housing of ill persons. A 5-day course of azithromycin was recommended for persons presenting with signs and symptoms of *C. pneumoniae* infection; a 14-day course of doxycycline was recommended for those who remained symptomatic after completing azithromycin. The last confirmed *C. pneumoniae* case was detected on 3 March 2010, 9 days after the outbreak investigation concluded; demographic and clinical data were not available for this inmate.

DISCUSSION

This report summarizes the largest *C. pneumoniae* outbreak confirmed by qPCR. The long duration of the outbreak (over 4 months) is consistent with *C. pneumoniae* outbreaks described in military barracks [17, 18] and contrasts with the shorter duration (1–2 months) often seen in long-term care facilities [6, 7]. The attack rates seen in this prison were lower than the median reported among long-term care facilities (46%), possibly due to lower prevalence of comorbid conditions as this facility was rated care level 2 by the BOP, and inmates did not have medical conditions that required more than routine appointments for monitoring [8]. The clinical presentation and spectrum of illness parallels those seen in other

C. pneumoniae outbreaks [11, 19], although we did not find a large number of asymptomatic qPCR-positive persons.

Inmates generally spent a large portion of the day together and slept on bunks spaced approximately 3–5 feet apart, facilitating transmission of *C. pneumoniae*. The increased risk of *C. pneumoniae* infection among white inmates may have been due to social interaction; inmates frequently congregated along racial or ethnic lines, increasing likelihood of transmission within.

Several studies have demonstrated an increased risk of *C. pneumoniae* illness, particularly severe disease, among the elderly and persons with asthma or chronic obstructive pulmonary disease (COPD) [7, 11, 20]. In this investigation, inmates with *C. pneumoniae* tended to be older than those who were not ill; however, this trend was not statistically significant. In addition, none of the 4 persons hospitalized during the outbreak were >45 years of age. We did not see any increased risk among persons with asthma, COPD, or other chronic medical conditions. The lack of association between *C. pneumoniae* and previously established risk factors may be attributed to a lack of statistical power to detect one or to the lower prevalence of chronic medical conditions in our inmate population than that seen at long-term health facilities and greater variability in age than military barracks. In previous studies, smoking has also been associated with an earlier illness onset; however, its prohibition in federal prisons did not allow us to determine current smoking status for inmates.

Postinfection carriage of *C. pneumoniae* is not uncommon, and several studies have used culture to document persistence of the organism for up to 12 months after acute infection [2, 21]. Although these studies were small, shedding of *C. pneumoniae* continued after completion of treatment with tetracycline or doxycycline (range, 5–31 days). Here we document persistence of the organism in the oropharynx by qPCR for up to 8 weeks following appropriate antibiotic therapy. Most participants in our follow-up study continued to experience cough symptoms for several weeks after their first qPCR-positive swab. Persistence of respiratory symptoms and *C. pneumoniae* detection after acute infection has been theorized to be due to chronic intracellular infection and sustained airway irritation [22]. In this outbreak, close living quarters and poor compliance with medications may have led to reexposure to *C. pneumoniae* and contributed to ongoing transmission.

Our findings may not fully represent the spectrum of *C. pneumoniae* illness because we were unable to identify all symptomatic inmates and, although qPCR is highly sensitive for detecting acute shedding, it was not used on cases that occurred earlier in the outbreak. We also utilized serological markers to identify *C. pneumoniae* infection, which may have cross-reacted with other *Chlamydia* species, specifically *C. trachomatis* [14, 15, 23]. Our results again demonstrate problems with specificity, as several inmates without symptoms who were negative by qPCR nonetheless had elevated IgM antibody levels. Although IgG measurements in paired sera are generally more reliable, timing is essential to diagnosis. Here, sera collected outside the acute and convalescent phases of illness may not have demonstrated a 4-fold increase distinguishing recent from past exposure.

Over the past several decades, US correctional facilities have become a congregate setting of increasing importance to public health. The number of incarcerated persons in US jails and prisons has reached historic highs, compounded by inmate overcrowding [24]. A disproportionate number of inmates have health problems that put them at risk for serious complications of respiratory infections, making the early detection and containment of outbreaks a priority for correctional healthcare and public health authorities [25]. Despite constitutional entitlement of all inmates to basic healthcare, correctional facilities present unique public health challenges: close quarters facilitate droplet transmission, and medical illness is often underreported due to fear of stigmatization or isolation. Control of respiratory outbreaks can be difficult because of poor compliance with recommended behavioral modifications (eg cough etiquette, medication compliance) and because routine respiratory precautions (eg masks, alcohol-based sanitizers, soap dispensers) are often not feasible in this setting.

Key lessons learned from this outbreak investigation include (1) diagnostic advantages of using qPCR to identify *C. pneumoniae* during respiratory outbreaks; (2) recognition that antibiotic therapy for *C. pneumoniae* may not readily reduce coughing or eliminate carriage; (3) importance of inmate education and elimination of medical copay to maximize case identification during outbreaks in the correctional setting; and (4) prioritization of hand hygiene as the key infection control measure in jails and prisons. Last, this investigation highlights the value of collaboration between public health and corrections officials to advance our understanding of respiratory outbreaks and their management.

Acknowledgments

Financial support. This work was funded by the Centers for Disease Control and Prevention.

References

1. Miyashita N, Fukano H, Okimoto N, et al. Clinical presentation of community-acquired *Chlamydia pneumoniae* pneumonia in adults. *Chest*. 2002; 121:1776–81. [PubMed: 12065338]
2. Grayston JT, Kuo C-c, Wang S-p, Altman J. A new *Chlamydia psittaci* strain, TWAR, isolated in acute respiratory tract infections. *N Engl J Med*. 1986; 315:161–8. [PubMed: 3724806]
3. File TM Jr, Tan JS. *Chlamydia pneumoniae* pneumonia. *Semin Respir Crit Care Med*. 2000; 21:285–94. [PubMed: 16088739]
4. Blasi F, Tarsia P, Aliberti S. *Chlamydophila pneumoniae*. *Clin Microbiol Infect*. 2009; 15:29–35. [PubMed: 19220337]
5. Miyashita N, Niki Y, Nakajima M, Fukano H, Matsushima T. Prevalence of asymptomatic infection with *Chlamydia pneumoniae* in subjectively healthy adults. *Chest*. 2001; 119:1416–9. [PubMed: 11348947]
6. Troy CJ, Peeling RW, Ellis AG, et al. *Chlamydia pneumoniae* as a new source of infectious outbreaks in nursing homes. *JAMA*. 1997; 277:1214–8. [PubMed: 9103345]
7. Miyashita N, Ouchi K, Shoji H, et al. Outbreak of *Chlamydophila pneumoniae* infection in long-term care facilities and an affiliated hospital. *J Med Microbiol*. 2005; 54:1243–7. [PubMed: 16278441]
8. Utsumi M, Makimoto K, Quiroshi N, Ashida N. Types of infectious outbreaks and their impact in elderly care facilities: a review of the literature. *Age Ageing*. 2010; 39:299–305. [PubMed: 20332371]

9. Marrie TJ, Peeling RW, Reid T, De Carolis E. Canadian Community-Acquired Pneumonia Investigators. *Chlamydia* species as a cause of community-acquired pneumonia in Canada. *Eur Respir J*. 2003; 21:779–84. [PubMed: 12765420]
10. Dawood F, Ambrose J, Russell B, et al. Outbreak of pneumonia in the setting of fatal pneumococcal meningitis among US Army trainees: potential role of *Chlamydia pneumoniae* infection. *BMC Infect Dis*. 2011; 11:157. [PubMed: 21635754]
11. Kauppinen MT, Herva E, Kujala P, Leinonen M, Saikku P, Syrjälä H. The etiology of community-acquired pneumonia among hospitalized patients during a *Chlamydia pneumoniae* epidemic in Finland. *J Infect Dis*. 1995; 172:1330–5. [PubMed: 7594672]
12. Dowell SF, Peeling RW, Boman J, et al. Standardizing *Chlamydia pneumoniae* assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). *Clin Infect Dis*. 2001; 33:492–503. [PubMed: 11462186]
13. Mitchell SL, Budhiraja S, Thurman KA, Lanier Thacker W, Winchell JM. Evaluation of two real-time PCR chemistries for the detection of *Chlamydophila pneumoniae* in clinical specimens. *Mol Cell Probes*. 2009; 23:309–11. [PubMed: 19647071]
14. Goldstein EJC, Kumar S, Hammerschlag MR. Acute respiratory infection due to *Chlamydia pneumoniae*: current status of diagnostic methods. *Clin Infect Dis*. 2007; 44:568–76. [PubMed: 17243062]
15. Benitez AJ, Thurman KA, Diaz MH, Conklin L, Kendig NE, Winchell JM. Comparison of real-time PCR and a microimmunofluorescence serological assay for detection of *Chlamydophila pneumoniae* infection in an outbreak investigation. *J Clin Microbiol*. 2012; 50:151–3. [PubMed: 22031704]
16. Thurman KA, Warner AK, Cowart KC, Benitez AJ, Winchell JM. Detection of *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella* spp. in clinical specimens using a single-tube multiplex real-time PCR assay. *Diagn Microbiol Infect Dis*. 2011; 70:1–9. [PubMed: 21397428]
17. Ekman M-R, Grayston JT, Visakorpi R, Kleemola M, Kuo C-c, Saikku P. An epidemic of infections due to *Chlamydia pneumoniae* in military conscripts. *Clin Infect Dis*. 1993; 17:420–5. [PubMed: 8218684]
18. Kleemola M, Saikku P, Visakorpi R, Wang SP, Grayston JT. Epidemics of pneumonia caused by TWAR, a new *Chlamydia* organism, in military trainees in Finland. *J Infect Dis*. 1988; 157:230–6. [PubMed: 3335808]
19. File TM, Plouffe JF, Breiman RF, Skelton SK. Clinical characteristics of *Chlamydia pneumoniae* infection as the sole cause of community-acquired pneumonia. *Clin Infect Dis*. 1999; 29:426–8. [PubMed: 10476753]
20. Metz G, Kraft M. Effects of atypical infections with *Mycoplasma* and *Chlamydia* on asthma. *Immunol Allergy Clin North Am*. 2010; 30:575–85. [PubMed: 21029940]
21. Hammerschlag MR, Chirgwin K, Roblin PM, et al. Persistent infection with *Chlamydia pneumoniae* following acute respiratory illness. *Clin Infect Dis*. 1992; 14:178–82. [PubMed: 1571425]
22. Blasi F, Aliberti S, Allegra L, et al. *Chlamydophila pneumoniae* induces a sustained airway hyperresponsiveness and inflammation in mice. *Respir Res*. 2007; 8:83. [PubMed: 18021431]
23. Tuuminen T, Varjo S, Ingman H, Weber T, Oksi J, Viljanen M. Prevalence of *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* immunoglobulin G and A antibodies in a healthy Finnish population as analyzed by quantitative enzyme immunoassays. *Clin Diagn Lab Immunol*. 2000; 7:734–8. [PubMed: 10973446]
24. Guerino, P. Prisoners in 2010. US Department of Justice, Bureau of Justice Statistics Bulletin; 2011. NCJ 236096. Available at: <http://www.bjs.gov/content/pub/pdf/p10.pdf>
25. John MR. The disease profile of Texas prison inmates. *Ann Epidemiol*. 2000; 10:71–3. [PubMed: 10691059]





Figure 1. Distribution of *Chlamydia pneumoniae* cases by date of symptom onset and residential housing unit during an outbreak at a federal correctional facility (N = 52). The last laboratory-confirmed *C. pneumoniae* case was detected on 3 March 2010; however, symptom onset data were not available.

**Figure 2.**

Antibiotic usage and persistence of *Chlamydia pneumoniae* carriage and symptoms over time among 40 cases of *C. pneumoniae* respiratory infection at a federal correctional facility.

*Indicates chest radiography–confirmed pneumonia. Abbreviations: AC, symptomatic, cleared (real-time polymerase chain reaction [qPCR] negative); AP, symptomatic, persistent infection (or reinfection); D, doxycycline; NS, not specified; SC, symptomatic, cleared (qPCR negative); SP, symptomatic, persistent infection (or reinfection); Z, azithromycin.

Table 1

Characteristics of Respiratory Illness Among Inmates Who Self-Referred for Care and Were Identified by a Random Sample During an Outbreak of *Chlamydia pneumoniae* in a Federal Correctional Facility (N = 52)

Characteristic	Self-Referred Cases (%) n = 33	Random Sample–Identified Cases (%) n = 19	All Cases (%) N = 52
Demographics			
Age, y, median (range) ^a	42 (22–78)	35 (24–59)	40 (22–78)
Race and ethnicity			
White	15 (45.5)	9 (47.4)	24 (46.2)
Asian/Pacific Islander	2 (6.0)	1 (5.3)	3 (5.8)
African American	9 (27.3)	4 (21.0)	13 (25.0)
Hispanic	1 (3.0)	5 (26.3)	6 (11.5)
Missing race data	6 (18.2)	0	6 (11.5)
Past medical history ^b			
Current or past smoker	17 (56.7)	9 (47.4)	26 (53.1)
Self-reported asthma diagnosis	3 (13.0)	5 (26.32)	8 (19.0)
Any self-reported chronic illness ^c	14 (42.4)	10 (52.6)	24 (46.2)
Unit of residence			
Housing unit X	10 (30.3)	11 (57.9)	21 (40.4)
Housing unit Y	23 (69.7)	8 (42.1)	31 (59.6)
Clinical characteristics and laboratory findings			
Pulmonary infiltrate on chest radiography ^b	15 (45.5)	NA	15 (45.5)
Any laboratory test positive ^b	29 (87.9)	19 (100)	48 (92.3)
PCR positive	23 (69.7)	8 (42.1)	31 (59.6)
4-fold increase in IgG ^d	5 (35.7)	1 (25.0)	6 (33.3)
Single IgM 10 ^e	24 (85.7)	14 (87.5)	38 (86.4)
Symptoms ^{b,f}			
Cough	29 (96.7)	19 (100)	48 (98.0)
Runny nose	18 (62.1)	17 (89.5)	35 (72.9)
Sore throat	23 (79.3)	12 (63.2)	35 (72.9)
Sputum	19 (65.5)	14 (73.7)	33 (68.8)
Fever or chills	25 (86.2)	7 (38.9)	32 (68.1)
Shortness of breath	24 (82.8)	4 (21.1)	28 (58.3)
Wheezing	21 (72.4)	6 (35.3)	27 (58.7)
Headache	18 (60.0)	4 (21.1)	22 (44.9)
Sinus pain/pressure	11 (44.0)	8 (42.1)	19 (43.2)
Joint or muscle aches	14 (48.3)	4 (21.1)	18 (37.5)
Ear pain/pressure	6 (23.1)	2 (10.5)	8 (17.8)
Diarrhea	6 (20.7)	0	6 (12.5)

Characteristic	Self-Referred Cases (%) n = 33	Random Sample-Identified Cases (%) n = 19	All Cases (%) N = 52
Vomiting	3 (10.3)	1 (5.3)	4 (8.3)
Median duration of cough, d	29 (1–64)	7 (3–42)	21 (1–64)

Abbreviations: IgG, immunoglobulin G; IgM, immunoglobulin M; NA, not applicable, none of the randomly selected inmates had x-rays taken; PCR, polymerase chain reaction.

^aData missing for 1 participant.

^bCases with missing data were excluded from these figures.

^cIncludes diabetes, asthma, chronic obstructive pulmonary disease, chronic liver disease, hypercholesterolemia, human immunodeficiency virus infection, obesity, atherosclerosis, and heart failure.

^dConvalescent sera were available from 14 self-presenting cases and 4 surveyed cases.

^eAcute sera were available from 28 self-presenting cases and 16 surveyed cases.

^fClinical symptoms obtained from the questionnaire were not available for 3 self-referred inmates; partial data were available for 4 self-referred inmates who completed a pilot questionnaire.

Table 2

Weighted Attack Rates of *Chlamydia pneumoniae* Infection Among 1574 Inmates in a Federal Correctional Facility by Housing Location

Housing Location	Weighted Attack Rate (95% CI)
Facility-wide	10.4 (7.0–13.8)
Housing unit X (all floors)	10.0 (5.3–14.7)
Floor 1	4.8 (0–12.0)
Floor 2	9.7 (2.2–17.3)
Floor 3	12.8 (4.6–21.0)
Housing unit Y (all floors)	10.9 (5.9–15.8)
Floor 1	0.8 (0–2.2)
Floor 2	13.6 (4.3–23.0)
Floor 3	12.5 (5.0–20.0)

Abbreviation: CI, confidence interval.

Univariate Comparison of Demographic and Clinical Characteristics Among Self-Referred and Randomly Selected Cases Compared to 155 Randomly Selected Controls During an Outbreak of *Chlamydia pneumoniae* Respiratory Illness in a Federal Correctional Facility

Table 3

Characteristic	Controls (n = 155)		Self-Referred Cases (n = 33)		Randomly Selected Cases (n = 19)	
	No. (%)	P Value	No. (%)	OR (95% CI)	No. (%)	RR (95% CI) P Value
Age >55 y ^a	8 (5.2)		4 (12.5)	2.6 (.7–9.2)	3 (15.8)	2.7 (.9–8.0) .065
Race ^a						
White	39 (25.5)		15 (55.6)	23.8 (3.0–187.7)	9 (47.4)	2.5 (.9–7.0) .079
African-American	44 (28.8)		9 (33.3)	12.7 (1.5–103.7)	4 (21.1)	1.1 (.3–3.9) .864
Latino-Hispanic	62 (40.5)		1 (3.7)	Referent	5 (26.6)	Referent ...
Other ^b	8 (5.2)		2 (7.4)	15.5 (1.3–190.9)	1 (5.3)	1.5 (.2–11.3) .701
No education beyond high school diploma/GED ^a	109 (73.6)		15 (65.2)	0.7 (.3–1.7)	10 (55.6)	0.5 (.2–1.2) .110
Smoker prior to incarceration ^a	106 (68.8)		17 (56.7)	0.6 (.3–1.3)	9 (47.4)	0.5 (.2–1.1) .066
History of asthma ^a	19 (12.3)		3 (13.0)	1.1 (.3–3.9)	5 (26.3)	2.2 (.9–5.6) .092
Unit Y residence compared to unit X	69 (44.5)		23 (69.7)	2.9 (1.3–6.4)	8 (42.1)	0.9 (.4–2.2) .842
Floor within unit Y						
Floor 1	12 (17.4)		1 (4.3)	0.2 (.0–1.3)	0	NA NA
Floor 2	26 (37.7)		5 (21.7)	0.4 (.1–1.1)	5 (62.5)	1.8 (.5, 7.0) .3798
Floor 3	31 (44.9)		17 (74.0)	Referent	3 (37.5)	Referent ...

Abbreviations: CI, confidence interval; GED, graduate equivalent degree; NA, not applicable; OR, odds ratio; RR, relative risk.

^aCases with missing data were excluded from these figures.

^bIncludes American Indian, Alaska Native, Asian, and Pacific Islander.

Table 4

Agreement of Antibody Testing With Real-Time Polymerase Chain Reaction Results During an Outbreak of *Chlamydia pneumoniae* in a Federal Correctional Facility, Among Samples From Inmates With and Without Acute Respiratory Illness^a

<i>C. pneumoniae</i> qPCR Result	Single IgM 1:10	Single IgG 1:512	4-Fold Increase in IgG
No ARI			
qPCR-positive (n = 1)	0/1 (0%)	1/1 (100%)	0/0
qPCR-negative (n = 37)	7/37 (18.9%)	23/37 (62.2%)	0/1 (0%)
ARI			
qPCR-positive (n = 25)	21/25 (84.0%)	24/25 (96.0%)	4/10 (40.0%)
qPCR-negative (n = 59)	17/59 (28.8%)	35/59 (59.3%)	2/22 (9.1%)

Results shown are the number positive/number tested (%).

Abbreviations: ARI, acute respiratory illness; IgG, immunoglobulin G; IgM, immunoglobulin M; qPCR, real-time polymerase chain reaction.

^a ARI defined as follows: cough lasting ≥ 3 days AND 1 or more of the following: myalgias, headache, sore throat; OR fever ≥ 37.2°C or chills AND 1 or more of the following: myalgias, headache, sore throat, cough ≥ 3 days.